A citation-based method for searching scientific literature

Stephen J Nicholls, A Michael Lincoff, Michelle Garcia, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian, Paul M Ridker, Kausik K Ray, Brian G Katona, Anders Himmelmann, Larrye E Loss, Martin Rensfeldt, Torbjörn Lundström, Rahul Agrawal, Venu Menon, Kathy Wolski, Steven E Nissen. JAMA 2020
Times Cited: 247







List of co-cited articles
2198 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
90

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
41

Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.
Are Annesønn Kalstad, Peder Langeland Myhre, Kristian Laake, Sjur Hansen Tveit, Erik Berg Schmidt, Paal Smith, Dennis Winston Trygve Nilsen, Arnljot Tveit, Morten Wang Fagerland, Svein Solheim,[...]. Circulation 2021
88
40

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
28

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
339
27

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
436
24

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Matthew J Budoff, Deepak L Bhatt, April Kinninger, Suvasini Lakshmanan, Joseph B Muhlestein, Viet T Le, Heidi T May, Kashif Shaikh, Chandana Shekar, Sion K Roy,[...]. Eur Heart J 2020
136
23

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
R Preston Mason, Peter Libby, Deepak L Bhatt. Arterioscler Thromb Vasc Biol 2020
127
21

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Aruna D Pradhan, Nina P Paynter, Brendan M Everett, Robert J Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R Hiatt, Shun Ishibashi, Wolfgang Koenig,[...]. Am Heart J 2018
203
19

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
18

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
18

Clinical review on triglycerides.
Ulrich Laufs, Klaus G Parhofer, Henry N Ginsberg, Robert A Hegele. Eur Heart J 2020
146
17

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
16

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
16

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
603
16

Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
15

Evinacumab for Homozygous Familial Hypercholesterolemia.
Frederick J Raal, Robert S Rosenson, Laurens F Reeskamp, G Kees Hovingh, John J P Kastelein, Paolo Rubba, Shazia Ali, Poulabi Banerjee, Kuo-Chen Chan, Daniel A Gipe,[...]. N Engl J Med 2020
192
15

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Joseph L Witztum, Daniel Gaudet, Steven D Freedman, Veronica J Alexander, Andres Digenio, Karren R Williams, Qingqing Yang, Steven G Hughes, Richard S Geary, Marcello Arca,[...]. N Engl J Med 2019
196
15


Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial.
Steven E Nissen, A Michael Lincoff, Kathy Wolski, Christie M Ballantyne, John J P Kastelein, Paul M Ridker, Kausik K Ray, Darren K McGuire, Dariush Mozaffarian, Wolfgang Koenig,[...]. JAMA Cardiol 2021
26
57

Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
14

A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
Tetsu Watanabe, Kaoru Ando, Hyuma Daidoji, Yoichiro Otaki, Shigeo Sugawara, Motoyuki Matsui, Eiichiro Ikeno, Osamu Hirono, Hiroshi Miyawaki, Yoshinori Yashiro,[...]. J Cardiol 2017
86
16

Triglycerides and cardiovascular disease.
Børge G Nordestgaard, Anette Varbo. Lancet 2014
696
14

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
371
14


Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.
Henry N Ginsberg, Chris J Packard, M John Chapman, Jan Borén, Carlos A Aguilar-Salinas, Maurizio Averna, Brian A Ference, Daniel Gaudet, Robert A Hegele, Sander Kersten,[...]. Eur Heart J 2021
69
18

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Christie M Ballantyne, Harold E Bays, John J Kastelein, Evan Stein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2012
235
12

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Brian A Ference, John J P Kastelein, Kausik K Ray, Henry N Ginsberg, M John Chapman, Chris J Packard, Ulrich Laufs, Clare Oliver-Williams, Angela M Wood, Adam S Butterworth,[...]. JAMA 2019
272
12

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
12

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Seth J Baum, Eunju Hurh, Joyce Kingsbury, Victoria J Bartlett, Amparo L Figueroa, Philip Piscitelli, Walter Singleton, Joseph L Witztum,[...]. Eur Heart J 2020
96
12


2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Donna K Arnett, Roger S Blumenthal, Michelle A Albert, Andrew B Buroker, Zachary D Goldberger, Ellen J Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J William McEvoy,[...]. Circulation 2019
11

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, Colm O'Dushlaine, Claudia Schurmann, Omri Gottesman, Shane McCarthy, Cristopher V Van Hout, Shannon Bruse, Hayes M Dansky,[...]. N Engl J Med 2017
431
11

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.
Salim S Virani, Pamela B Morris, Anandita Agarwala, Christie M Ballantyne, Kim K Birtcher, Penny M Kris-Etherton, Amanda B Ladden-Stirling, Michael Miller, Carl E Orringer, Neil J Stone. J Am Coll Cardiol 2021
40
27

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Luigi Tavazzi, Aldo P Maggioni, Roberto Marchioli, Simona Barlera, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Gian Luigi Nicolosi, Maurizio Porcu, Gianni Tognoni. Lancet 2008
896
11

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
Yasushi Saito, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Atherosclerosis 2008
216
10

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
Veronica J Alexander, Shuting Xia, Eunju Hurh, Steven G Hughes, Louis O'Dea, Richard S Geary, Joseph L Witztum, Sotirios Tsimikas. Eur Heart J 2019
103
10

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Mark J Graham, Richard G Lee, Teresa A Brandt, Li-Jung Tai, Wuxia Fu, Raechel Peralta, Rosie Yu, Eunju Hurh, Erika Paz, Bradley W McEvoy,[...]. N Engl J Med 2017
351
10

Evinacumab in Patients with Refractory Hypercholesterolemia.
Robert S Rosenson, Lesley J Burgess, Christoph F Ebenbichler, Seth J Baum, Erik S G Stroes, Shazia Ali, Nagwa Khilla, Robert Hamlin, Robert Pordy, Yuping Dong,[...]. N Engl J Med 2020
81
12

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Jacy Crosby, Gina M Peloso, Paul L Auer, David R Crosslin, Nathan O Stitziel, Leslie A Lange, Yingchang Lu, Zheng-zheng Tang, He Zhang, George Hindy,[...]. N Engl J Med 2014
713
10

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
9

Major lipids, apolipoproteins, and risk of vascular disease.
Emanuele Di Angelantonio, Nadeem Sarwar, Philip Perry, Stephen Kaptoge, Kausik K Ray, Alexander Thompson, Angela M Wood, Sarah Lewington, Naveed Sattar, Chris J Packard,[...]. JAMA 2009
9

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
9

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.
Brian Olshansky, Mina K Chung, Matthew J Budoff, Sephy Philip, Lixia Jiao, Ralph T Doyle, Christina Copland, Alex Giaquinto, Rebecca A Juliano, Deepak L Bhatt. Eur Heart J Suppl 2020
28
32

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,[...]. Lancet 2005
9

Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
Om P Ganda, Deepak L Bhatt, R Preston Mason, Michael Miller, William E Boden. J Am Coll Cardiol 2018
112
9

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. J Am Coll Cardiol 2019
152
9

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Ann C Skulas-Ray, Peter W F Wilson, William S Harris, Eliot A Brinton, Penny M Kris-Etherton, Chesney K Richter, Terry A Jacobson, Mary B Engler, Michael Miller, Jennifer G Robinson,[...]. Circulation 2019
162
9

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard, Anne Tybjærg-Hansen. N Engl J Med 2014
597
9

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
Nadeem Sarwar, Manjinder S Sandhu, Sally L Ricketts, Adam S Butterworth, Emanuele Di Angelantonio, S Matthijs Boekholdt, Willem Ouwehand, Hugh Watkins, Nilesh J Samani, Danish Saleheen,[...]. Lancet 2010
490
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.